c-Met/HGFR
c-Met/HGFR inhibitors target the Hepatocyte Growth Factor Receptor (c-Met), a tyrosine kinase involved in cellular processes such as growth, motility, and morphogenesis. c-Met signaling is implicated in cancer progression, metastasis, and resistance to therapies. Inhibiting c-Met can disrupt tumor growth and spread, making these inhibitors valuable in cancer research. At CymitQuimica, we offer c-Met/HGFR inhibitors to support your research in oncology, metastasis, and targeted cancer therapies.
Found 128 products of "c-Met/HGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Formula:C41H42FN5O7Purity:99.75%Color and Shape:SolidMolecular weight:735.8PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Formula:C19H16N8OPurity:98.41% - 98.55%Color and Shape:SolidMolecular weight:372.38Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Formula:C17H15N9Purity:98.12%Color and Shape:SolidMolecular weight:345.36BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Formula:C23H15ClF2N4O3Purity:98% - 99.69%Color and Shape:SolidMolecular weight:468.84Hepln-13
CAS:<p>Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.</p>Formula:C17H13BrN2Purity:97.67%Color and Shape:SolidMolecular weight:325.2XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Formula:C29H25FN4O5Purity:98.60%Color and Shape:SolidMolecular weight:528.53NPS-1034
CAS:<p>NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.</p>Formula:C31H23F2N5O3Purity:98.48%Color and Shape:SolidMolecular weight:551.54Merestinib dihydrochloride
CAS:<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Formula:C30H24Cl2F2N6O3Color and Shape:SolidMolecular weight:625.45AMG-337
CAS:<p>AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).</p>Formula:C23H22FN7O3Purity:99.26% - 99.9%Color and Shape:SolidMolecular weight:463.46Afatinib Dimaleate
CAS:<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Formula:C32H33ClFN5O11Purity:98.11% - 99.87%Color and Shape:SolidMolecular weight:718.08SCR-1481B1
CAS:<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Formula:C32H40ClF2N6O13PPurity:98.07%Color and Shape:SolidMolecular weight:821.12X-376
CAS:<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Formula:C25H25Cl2FN6O3Purity:97.87%Color and Shape:SolidMolecular weight:547.41Golvatinib
CAS:<p>Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor</p>Formula:C33H37F2N7O4Purity:98.24% - ≥95%Color and Shape:SolidMolecular weight:633.69c-Kit-IN-1
CAS:<p>c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).</p>Formula:C26H21F2N5O3Purity:98.72% - 98.73%Color and Shape:SolidMolecular weight:489.47Tivantinib
CAS:<p>Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.</p>Formula:C23H19N3O2Purity:98% - 99.41%Color and Shape:SolidMolecular weight:369.42Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Formula:C26H21F3N4O4Purity:99.67% - 99.75%Color and Shape:SolidMolecular weight:510.46Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C31H29FN4O5Purity:99.95% - 99.98%Color and Shape:SolidMolecular weight:556.58Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Formula:C23H18ClFN6OPurity:98.62% - 99.81%Color and Shape:SolidMolecular weight:448.89
